{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T03:12:48Z","timestamp":1778641968303,"version":"3.51.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-04780-y","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T06:26:27Z","timestamp":1775111187000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world utility of platelet count, hemoglobin, and iron levels as predictors of clinical response to vedolizumab in patients with ulcerative colitis: a retrospective, single-center study in Poland"],"prefix":"10.1186","volume":"26","author":[{"given":"Aleksandra","family":"Sobolewska-W\u0142odarczyk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub","family":"Orli\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u017baneta","family":"Witas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0141ukasz","family":"Wo\u017aniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuzanna","family":"\u0141yso\u0144","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"G\u0105siorowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"issue":"10080","key":"4780_CR1","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","volume":"389","author":"R Ungaro","year":"2017","unstructured":"Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389(10080):1756\u201370. https:\/\/doi.org\/10.1016\/S0140-6736(16)32126-2.","journal-title":"Lancet"},{"issue":"1","key":"4780_CR2","doi-asserted-by":"publisher","first-page":"103017","DOI":"10.1016\/j.autrev.2021.103017","volume":"21","author":"H Nakase","year":"2022","unstructured":"Nakase H, Sato N, Mizuno N, Ikawa Y. The influence of cytokines on the complex pathology of ulcerative colitis. Autoimmun Rev. 2022;21(1):103017. https:\/\/doi.org\/10.1016\/j.autrev.2021.103017.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"4780_CR3","doi-asserted-by":"publisher","first-page":"100851","DOI":"10.1016\/j.disamonth.2019.02.004","volume":"65","author":"M Gajendran","year":"2019","unstructured":"Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, et al. A comprehensive review and update on ulcerative colitis. Dis Mon. 2019;65(3):100851. https:\/\/doi.org\/10.1016\/j.disamonth.2019.02.004.","journal-title":"Dis Mon"},{"issue":"34\u201335","key":"4780_CR4","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3238\/arztebl.2020.0564","volume":"117","author":"T Kucharzik","year":"2020","unstructured":"Kucharzik T, Koletzko S, Kannengie\u00dfer K, Digna\u00df A. Ulcerative colitis\u2014diagnostic and therapeutic algorithms. Dtsch Arztebl Int. 2020;117(34\u201335):564\u201373. https:\/\/doi.org\/10.3238\/arztebl.2020.0564.","journal-title":"Dtsch Arztebl Int"},{"issue":"3","key":"4780_CR5","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/apt.15876","volume":"52","author":"S Singh","year":"2020","unstructured":"Singh S, Kim J, Zhu W, Dulai PS, Sandborn WJ, Jairath V. No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy. Aliment Pharmacol Ther. 2020;52(3):481\u201391. https:\/\/doi.org\/10.1111\/apt.15876.","journal-title":"Aliment Pharmacol Ther"},{"key":"4780_CR6","doi-asserted-by":"publisher","first-page":"175628482211381","DOI":"10.1177\/17562848221138160","volume":"15","author":"N Aslam","year":"2022","unstructured":"Aslam N, Lo SW, Sikafi R, Barnes T, Segal J, Smith PJ, et al. A review of the therapeutic management of ulcerative colitis. Ther Adv Gastroenterol. 2022;15:17562848221138160. https:\/\/doi.org\/10.1177\/17562848221138160.","journal-title":"Ther Adv Gastroenterol"},{"key":"4780_CR7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.48338","author":"H Ashraf","year":"2023","unstructured":"Ashraf H, Bodapati A, Hanif A, Okafor DK, Katyal G, Kaur G, et al. Safety and efficacy of biologic therapies (ustekinumab and vedolizumab) in the treatment of inflammatory bowel disease (IBD): a systematic review. Cureus. 2023. https:\/\/doi.org\/10.7759\/cureus.48338.","journal-title":"Cureus"},{"key":"4780_CR8","doi-asserted-by":"publisher","first-page":"e2210","DOI":"10.1002\/hsr2.2210","volume":"7","author":"S Azadbakht","year":"2024","unstructured":"Azadbakht S, Seighali M, Azadbakht S, Azadbakht M. Effectiveness of adalimumab in severe ulcerative colitis: a systematic review and a meta-analysis. Health Sci Rep. 2024;7:e2210. https:\/\/doi.org\/10.1002\/hsr2.2210.","journal-title":"Health Sci Rep"},{"issue":"3","key":"4780_CR9","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3390\/jcm14031001","volume":"14","author":"M Colwill","year":"2025","unstructured":"Colwill M, Baillie S, Clough J, Pollok R, Poullis A, Patel K, et al. Role of mirikizumab in the treatment of inflammatory bowel disease\u2014from bench to bedside. J Clin Med. 2025;14(3):1001. https:\/\/doi.org\/10.3390\/jcm14031001.","journal-title":"J Clin Med"},{"issue":"1","key":"4780_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/ibd\/izab011","volume":"28","author":"C Taxonera","year":"2022","unstructured":"Taxonera C, Olivares D, Alba C. Real-world effectiveness and safety of tofacitinib in patients with ulcerative colitis: systematic review with meta-analysis. Inflamm Bowel Dis. 2022;28(1):32\u201340. https:\/\/doi.org\/10.1093\/ibd\/izab011.","journal-title":"Inflamm Bowel Dis"},{"key":"4780_CR11","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.3390\/jcm14051695","volume":"14","author":"M Kaniewska","year":"2025","unstructured":"Kaniewska M, Lewandowski K, Krogulecki M, Filipiuk A, Gonciarz M, Pietrzak A, et al. Efficacy of upadacitinib induction treatment in moderate-to-severe ulcerative colitis including intestinal ultrasound assessment: a multicenter, real-world observational study. J Clin Med. 2025;14:1695. https:\/\/doi.org\/10.3390\/jcm14051695.","journal-title":"J Clin Med"},{"key":"4780_CR12","doi-asserted-by":"publisher","first-page":"e240193","DOI":"10.57264\/cer-2024-0193","volume":"14","author":"V Jairath","year":"2025","unstructured":"Jairath V, Raine T, Leahy TP, Potluri R, Wosik K, Gruben D, et al. Matching-adjusted indirect comparisons of efficacy outcomes between etrasimod and ozanimod for moderately to severely active ulcerative colitis. J Comp Eff Res. 2025;14:e240193. https:\/\/doi.org\/10.57264\/cer-2024-0193.","journal-title":"J Comp Eff Res"},{"issue":"15","key":"4780_CR13","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.3748\/wjg.v18","volume":"18","author":"A Biondi","year":"2012","unstructured":"Biondi A, Zoccali M, Costa S, Troci A, Contessini-Avesani E, Fichera A. Surgical treatment of ulcerative colitis in the biologic therapy era. World J Gastroenterol. 2012;18(15):1861\u201370. https:\/\/doi.org\/10.3748\/wjg.v18.","journal-title":"World J Gastroenterol"},{"key":"4780_CR14","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2147\/CEG.S293272","volume":"14","author":"J Gubatan","year":"2021","unstructured":"Gubatan J, Keyashian K, Rubin SJS, Wang J, Buckman CA, Sinha S. Anti-integrins for the treatment of inflammatory bowel disease: current evidence and perspectives. Clin Exp Gastroenterol. 2021;14:333\u201342. https:\/\/doi.org\/10.2147\/CEG.S293272.","journal-title":"Clin Exp Gastroenterol"},{"issue":"3","key":"4780_CR15","doi-asserted-by":"publisher","first-page":"407","DOI":"10.18999\/nagjms.86.3.407","volume":"86","author":"G Kajikawa","year":"2024","unstructured":"Kajikawa G, Sawada T, Nakamura M, Yamamura T, Maeda K, Ishikawa E, et al. Predictors of the efficacy of vedolizumab in patients with ulcerative colitis. Nagoya J Med Sci. 2024;86(3):407\u201321. https:\/\/doi.org\/10.18999\/nagjms.86.3.407.","journal-title":"Nagoya J Med Sci"},{"issue":"12","key":"4780_CR16","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/j.cgh.2018.04.040","volume":"16","author":"E Dreesen","year":"2018","unstructured":"Dreesen E, Verstockt B, Bian S, de Bruyn M, Compernolle G, Tops S, et al. Evidence to support monitoring of vedolizumab trough concentrations in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2018;16(12):1937\u2013e468. https:\/\/doi.org\/10.1016\/j.cgh.2018.04.040.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"20","key":"4780_CR17","doi-asserted-by":"publisher","first-page":"e38759","DOI":"10.1097\/MD.0000000000038759","volume":"103","author":"J Yan","year":"2024","unstructured":"Yan J, Ding X, Wu J, Liu A, Fang L, Xu Y. Real-life effectiveness and safety of vedolizumab in moderate-to-severe ulcerative colitis: a single-center experience in northern China. Med (Baltim). 2024;103(20):e38759. https:\/\/doi.org\/10.1097\/MD.0000000000038759.","journal-title":"Med (Baltim)"},{"key":"4780_CR18","doi-asserted-by":"publisher","first-page":"1524307","DOI":"10.3389\/fmed.2025.1524307","volume":"12","author":"J Yan","year":"2025","unstructured":"Yan J, Wu J, Wang R, Meng P, Liu A, Xu Y. The systemic immune-inflammation index is superior to predicting clinical remission and relapse for ulcerative colitis patients treated with vedolizumab. Front Med (Lausanne). 2025;12:1524307. https:\/\/doi.org\/10.3389\/fmed.2025.1524307.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"4780_CR19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/cam4.4940","volume":"12","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Chen S, Chen H, Li W. A comprehensive analysis of Glasgow prognostic score (GPS)\/the modified Glasgow prognostic score (mGPS) on immune checkpoint inhibitor efficacy among patients with advanced cancer. Cancer Med. 2023;12(1):38\u201348. https:\/\/doi.org\/10.1002\/cam4.4940.","journal-title":"Cancer Med"},{"key":"4780_CR20","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41598-017-18771-3","volume":"8","author":"C Zhao","year":"2018","unstructured":"Zhao C, Ding C, Xie T, Zhang T, Dai X, Wei Y, et al. Validation and optimization of the systemic inflammation-based modified Glasgow prognostic score in predicting postoperative outcome of inflammatory bowel disease: preliminary data. Sci Rep. 2018;8:148. https:\/\/doi.org\/10.1038\/s41598-017-18771-3.","journal-title":"Sci Rep"},{"issue":"4","key":"4780_CR21","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.gtc.2020.08.003","volume":"49","author":"BS Pabla","year":"2020","unstructured":"Pabla BS, Schwartz DA. Assessing severity of disease in patients with ulcerative colitis. Gastroenterol Clin North Am. 2020;49(4):671\u201388. https:\/\/doi.org\/10.1016\/j.gtc.2020.08.003.","journal-title":"Gastroenterol Clin North Am"},{"issue":"9","key":"4780_CR22","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1007\/s10620-012-2081-z","volume":"57","author":"SM Quezada","year":"2012","unstructured":"Quezada SM, Cross RK. Association of age at diagnosis and ulcerative colitis phenotype. Dig Dis Sci. 2012;57(9):2402\u20137. https:\/\/doi.org\/10.1007\/s10620-012-2081-z.","journal-title":"Dig Dis Sci"},{"key":"4780_CR23","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s12876-023-02640-7","volume":"23","author":"A Armuzzi","year":"2023","unstructured":"Armuzzi A, Hart A, Cappelleri JC, Mammar N, Hur P, Hoskin B, et al. Characteristics, clinical outcomes and patient-reported outcomes of patients with ulcerative colitis receiving tofacitinib: a real-world survey in the United States and five European countries. BMC Gastroenterol. 2023;23:248. https:\/\/doi.org\/10.1186\/s12876-023-02640-7.","journal-title":"BMC Gastroenterol"},{"key":"4780_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-03078-3","author":"T Hibi","year":"2025","unstructured":"Hibi T, Kobayashi T, Tanaka M, Osaga S, Potts Bleakman AJ, Hunter Gibble T, et al. Patient and health care professional perspectives on the burden and daily life impact of ulcerative colitis and Crohn\u2019s disease: results from the Japanese CONFIDE study. Adv Ther. 2025. https:\/\/doi.org\/10.1007\/s12325-024-03078-3.","journal-title":"Adv Ther"},{"issue":"11","key":"4780_CR25","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1007\/s11136-023-03435-9","volume":"32","author":"BC Olsen","year":"2023","unstructured":"Olsen BC, Opheim R, Kristensen VA, H\u00f8ivik ML, Lund C, Aabrekk TB, et al. Health-related quality of life in patients with newly diagnosed inflammatory bowel disease: an observational prospective cohort study (IBSEN III). Qual Life Res. 2023;32(11):2951\u201364. https:\/\/doi.org\/10.1007\/s11136-023-03435-9.","journal-title":"Qual Life Res"},{"key":"4780_CR26","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s12876-023-02648-z","volume":"23","author":"M Pakdin","year":"2023","unstructured":"Pakdin M, Zarei L, Bagheri Lankarani K, Ghahramani S. The cost of illness analysis of inflammatory bowel disease. BMC Gastroenterol. 2023;23:259. https:\/\/doi.org\/10.1186\/s12876-023-02648-z.","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"4780_CR27","doi-asserted-by":"publisher","first-page":"60","DOI":"10.5114\/pg.2017.66324","volume":"12","author":"P Kawalec","year":"2017","unstructured":"Kawalec P, Stawowczyk E, Mossakowska M, Pilc A. Disease activity, quality of life, and indirect costs of ulcerative colitis in Poland. Prz Gastroenterol. 2017;12(1):60\u20135. https:\/\/doi.org\/10.5114\/pg.2017.66324.","journal-title":"Prz Gastroenterol"},{"issue":"1","key":"4780_CR28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4103\/sjg.sjg_249_24","volume":"31","author":"N Azzam","year":"2025","unstructured":"Azzam N, Alharbi O, Altuwaijri M, Alruthia Y, Alfarhan H, Alshankiti S, et al. The effectiveness of vedolizumab in advanced therapy-experienced ulcerative colitis patients: real world data from the Inflammatory Bowel Disease of the Middle East (IBD-ME) Registry Group. Saudi J Gastroenterol. 2025;31(1):34\u201340. https:\/\/doi.org\/10.4103\/sjg.sjg_249_24.","journal-title":"Saudi J Gastroenterol"},{"issue":"7","key":"4780_CR29","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.3390\/jcm9072126","volume":"9","author":"P Scarozza","year":"2020","unstructured":"Scarozza P, De Cristofaro E, Scucchi L, Rocchetti I, Marafini I, Neri B, et al. Effect of vedolizumab on anemia of chronic disease in patients with inflammatory bowel diseases. J Clin Med. 2020;9(7):2126. https:\/\/doi.org\/10.3390\/jcm9072126.","journal-title":"J Clin Med"},{"key":"4780_CR30","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12876-021-01604-z","volume":"21","author":"L M\u00fchl","year":"2021","unstructured":"M\u00fchl L, Becker E, M\u00fcller TM, Atreya R, Atreya I, Neurath MF, et al. Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study. BMC Gastroenterol. 2021;21:151. https:\/\/doi.org\/10.1186\/s12876-021-01604-z.","journal-title":"BMC Gastroenterol"},{"issue":"3","key":"4780_CR31","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s10620-021-06907-5","volume":"67","author":"G Bamias","year":"2022","unstructured":"Bamias G, Kokkotis G, Gizis M, Kapizioni C, Karmiris K, Koureta E, et al. Predictors of response to vedolizumab in patients with ulcerative colitis: results from the Greek VEDO-IBD cohort. Dig Dis Sci. 2022;67(3):1007\u201317. https:\/\/doi.org\/10.1007\/s10620-021-06907-5.","journal-title":"Dig Dis Sci"},{"issue":"8","key":"4780_CR32","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1093\/ibd\/izad010","volume":"29","author":"R Loveikyte","year":"2023","unstructured":"Loveikyte R, Bourgonje AR, Van Der Reijden JJ, Bulthuis MLC, Hawinkels LJAC, Visschedijk MC, et al. Hepcidin and iron status in patients with inflammatory bowel disease undergoing induction therapy with vedolizumab or infliximab. Inflamm Bowel Dis. 2023;29(8):1272\u201384. https:\/\/doi.org\/10.1093\/ibd\/izad010.","journal-title":"Inflamm Bowel Dis"},{"key":"4780_CR33","doi-asserted-by":"publisher","first-page":"589","DOI":"10.2147\/JIR.S500600","volume":"18","author":"K Su","year":"2025","unstructured":"Su K, Xiao S, Wang M, Wang K, Fan Q, Sha S, et al. Predictive value of albumin to fibrinogen ratio and CALLY index for diagnosis of ulcerative colitis and mucosal healing after vedolizumab treatment. J Inflamm Res. 2025;18:589\u2013600. https:\/\/doi.org\/10.2147\/JIR.S500600.","journal-title":"J Inflamm Res"},{"issue":"10","key":"4780_CR34","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1093\/ibd\/izaa062","volume":"26","author":"L Bertani","year":"2020","unstructured":"Bertani L, Rossari F, Barberio B, Demarzo MG, Tapete G, Albano E, et al. Novel prognostic biomarkers of mucosal healing in ulcerative colitis patients treated with anti-TNF: neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio. Inflamm Bowel Dis. 2020;26(10):1579\u201387. https:\/\/doi.org\/10.1093\/ibd\/izaa062.","journal-title":"Inflamm Bowel Dis"},{"key":"4780_CR35","doi-asserted-by":"publisher","first-page":"e938827","DOI":"10.12659\/MSM.938827","volume":"29","author":"M Warpechowski","year":"2023","unstructured":"Warpechowski M, Warpechowski J, Pie\u0144kowska A, Saga\u0142a S, Milewski R. Neutrophil-to-platelet ratio in patients with ulcerative colitis treated with infliximab or vedolizumab: a retrospective, single-center study in Poland. Med Sci Monit. 2023;29:e938827. https:\/\/doi.org\/10.12659\/MSM.938827.","journal-title":"Med Sci Monit"},{"issue":"9","key":"4780_CR36","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.dld.2021.11.014","volume":"54","author":"M Attauabi","year":"2022","unstructured":"Attauabi M, Madsen GR, Bendtsen F, Seidelin JB, Burisch J. Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn\u2019s disease \u2013 a systematic review with meta-analysis. Dig Liver Dis. 2022;54(9):1168\u201378. https:\/\/doi.org\/10.1016\/j.dld.2021.11.014.","journal-title":"Dig Liver Dis"},{"issue":"9","key":"4780_CR37","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1177\/2050640620948802","volume":"8","author":"FS Macaluso","year":"2020","unstructured":"Macaluso FS, Fries W, Renna S, Viola A, Muscianisi M, Cappello M, et al. Effectiveness and safety of vedolizumab in biologically na\u00efve patients: a real-world multi-centre study. United Eur Gastroenterol J. 2020;8(9):1045\u201355. https:\/\/doi.org\/10.1177\/2050640620948802.","journal-title":"United Eur Gastroenterol J"},{"key":"4780_CR38","doi-asserted-by":"publisher","DOI":"10.14309\/00000434-201810001-00660","author":"GJ Eustace","year":"2018","unstructured":"Eustace GJ, Almario CV, Spiegel B, Weaver AS, Siegel C, Melmed G. Home-based infusions for inflammatory bowel disease from the provider and patient perspective: 660. Am J Gastroenterol. 2018. https:\/\/doi.org\/10.14309\/00000434-201810001-00660.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"4780_CR39","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/1751-2980.13270","volume":"25","author":"RP Meng","year":"2024","unstructured":"Meng RP, Hu BW, Yang YL, Liu LY, Huang HY, Li CZ, et al. Effectiveness and safety of vedolizumab and infliximab in biologic-na\u00efve patients with moderate-to-severe ulcerative colitis: a multicenter, retrospective cohort study. J Dig Dis. 2024;25(4):230\u20137. https:\/\/doi.org\/10.1111\/1751-2980.13270.","journal-title":"J Dig Dis"},{"key":"4780_CR40","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2024.00063","author":"T Kobayashi","year":"2025","unstructured":"Kobayashi T, Hisamatsu T, Motoya S, Fujii T, Kunisaki R, Shibuya T, et al. Factors affecting 1-year persistence with vedolizumab for ulcerative colitis: a multicenter, retrospective real-world study. Intest Res. 2025. https:\/\/doi.org\/10.5217\/ir.2024.00063.","journal-title":"Intest Res"},{"issue":"6","key":"4780_CR41","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s40266-022-00943-0","volume":"39","author":"W Fries","year":"2022","unstructured":"Fries W, Demarzo MG, Navarra G, Viola A. Ulcerative colitis in adulthood and in older patients: same disease, same outcome, same risks? Drugs Aging. 2022;39(6):441\u201352. https:\/\/doi.org\/10.1007\/s40266-022-00943-0.","journal-title":"Drugs Aging"},{"key":"4780_CR42","doi-asserted-by":"publisher","first-page":"030006052311840","DOI":"10.1177\/03000605231184046","volume":"51","author":"Z Lian","year":"2023","unstructured":"Lian Z, Hu J, Cheng C, Liu Y, Zhu L, Shen H. Association with controlling nutritional status score and disease activity of ulcerative colitis. J Int Med Res. 2023;51:03000605231184046. https:\/\/doi.org\/10.1177\/03000605231184046.","journal-title":"J Int Med Res"},{"issue":"2","key":"4780_CR43","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s12325-016-0467-6","volume":"34","author":"V Yajnik","year":"2017","unstructured":"Yajnik V, Khan N, Dubinsky M, Axler J, James A, Abhyankar B, et al. Efficacy and safety of vedolizumab in ulcerative colitis and Crohn\u2019s disease patients stratified by age. Adv Ther. 2017;34(2):542\u201359. https:\/\/doi.org\/10.1007\/s12325-016-0467-6.","journal-title":"Adv Ther"},{"key":"4780_CR44","doi-asserted-by":"publisher","unstructured":"Lie MRKL, Paulides E, van der Woude CJ. Patient sex does not affect endoscopic outcomes of biologicals in inflammatory bowel disease but is associated with adverse events. Int J Colorectal Dis. 2020:35(8):1489\u2013500. https:\/\/doi.org\/10.1007\/s00384-020-03663-2","DOI":"10.1007\/s00384-020-03663-2"},{"issue":"3","key":"4780_CR45","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00384-022-04098-7","volume":"37","author":"C Schmidt","year":"2022","unstructured":"Schmidt C, Bokemeyer B, L\u00fcgering A, Bettenworth D, Teich N, Fischer I, et al. Clinical predictors for a complicated course of disease in an inception cohort of patients with ulcerative colitis: results from the prospective, observational EPICOL study. Int J Colorectal Dis. 2022;37(3):485\u201393. https:\/\/doi.org\/10.1007\/s00384-022-04098-7.","journal-title":"Int J Colorectal Dis"},{"issue":"4","key":"4780_CR46","doi-asserted-by":"publisher","first-page":"926","DOI":"10.3390\/jcm13040926","volume":"13","author":"KO Gradel","year":"2024","unstructured":"Gradel KO, N\u00f8rg\u00e5rd BM, Friedman S, Kjeldsen J, Larsen MD. Longitudinal measurements of blood biomarkers in patients with Crohn\u2019s disease or ulcerative colitis treated with infliximab: only the latest values in the induction period predict treatment failure. J Clin Med. 2024;13(4):926. https:\/\/doi.org\/10.3390\/jcm13040926.","journal-title":"J Clin Med"},{"issue":"3","key":"4780_CR47","doi-asserted-by":"publisher","first-page":"214","DOI":"10.5217\/ir.2014.12.3.214","volume":"12","author":"HI Seo","year":"2014","unstructured":"Seo HI, Park DI, Kim TO, Kim YS, Lee SH, Kim JW, et al. The effect of infliximab on patients with ulcerative colitis in Korea. Intest Res. 2014;12(3):214\u201320. https:\/\/doi.org\/10.5217\/ir.2014.12.3.214.","journal-title":"Intest Res"},{"issue":"12","key":"4780_CR48","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.3748\/wjg.v20.i12.3180","volume":"20","author":"E Voudoukis","year":"2014","unstructured":"Voudoukis E, Karmiris K, Koutroubakis IE. Multipotent role of platelets in inflammatory bowel diseases: a clinical approach. World J Gastroenterol. 2014;20(12):3180\u201390. https:\/\/doi.org\/10.3748\/wjg.v20.i12.3180.","journal-title":"World J Gastroenterol"},{"issue":"17","key":"4780_CR49","doi-asserted-by":"publisher","first-page":"6218","DOI":"10.3390\/ijms21176218","volume":"21","author":"V Josa","year":"2020","unstructured":"Josa V, Ferenczi S, Szalai R, Fuder E, Kuti D, Horvath K, et al. Thrombocytosis and effects of IL-6 knock-out in a colitis-associated cancer model. Int J Mol Sci. 2020;21(17):6218. https:\/\/doi.org\/10.3390\/ijms21176218.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"4780_CR50","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.mcna.2016.09.005","volume":"101","author":"PG Fraenkel","year":"2017","unstructured":"Fraenkel PG. Anemia of inflammation: a review. Med Clin North Am. 2017;101(2):285\u201396. https:\/\/doi.org\/10.1016\/j.mcna.2016.09.005.","journal-title":"Med Clin North Am"},{"issue":"6","key":"4780_CR51","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.3390\/biomedicines11061553","volume":"11","author":"A Levartovsky","year":"2023","unstructured":"Levartovsky A, Cohen I, Abitbol CM, Yavzori M, Fudim E, Picard O, et al. Do vedolizumab trough levels predict the outcome of subsequent therapy in inflammatory bowel disease? Biomedicines. 2023;11(6):1553. https:\/\/doi.org\/10.3390\/biomedicines11061553.","journal-title":"Biomedicines"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04780-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04780-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04780-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T02:26:08Z","timestamp":1778639168000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04780-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4780"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04780-y","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Studies that do not qualify as medical experiments, including retrospective analyses relying solely on previously collected clinical data, are exempt from the requirement of obtaining approval from a bioethics committee. Therefore, no approval was requested from the bioethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"290"}}